Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Illinois: - OSF Saint Anthony's Health Center — Alton, Illinois
- Rush-Copley Medical Center — Aurora, Illinois
- Advocate Outpatient Center - Aurora — Aurora, Illinois
- Advocate Good Shepherd Hospital — Barrington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Illinois: - Northwest Community Hospital — Arlington Heights, Illinois
- Rush-Copley Medical Center — Aurora, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- SIH Cancer Institute — Carterville, Illinois
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in Illinois: - Illinois Cancer Specialists (ICS) ( Site 8010) — Arlington Heights, Illinois
- Southern Illinois Hospital Services ( Site 9547) — Carterville, Illinois
- Orchard Healthcare Research Inc. ( Site 0014) — Skokie, Illinois
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in Illinois: - Northwestern University — Chicago, Illinois
- Southern Illinois University-Simmons — Springfield, Illinois
- Carle Foundation Cancer Institute-Urbana — Urbana, Illinois
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Illinois: - Research Site — Chicago, Illinois
- Research Site — Decatur, Illinois
- Research Site — Elmhurst, Illinois
- Research Site — Naperville, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients…
Sponsor: BeOne Medicines
NCT ID: NCT07492641
Sites in Illinois: - Hope and Healing Cancer Services — Hinsdale, Illinois
- Cancer Care Specialists For Illinois — OFallon, Illinois
Phase 3 Recruiting Industry
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…
Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in Illinois: - Research Site — Arlington Heights, Illinois
- Research Site — Chicago, Illinois
- Research Site — Evanston, Illinois
- Research Site — Park Ridge, Illinois
- Research Site — Schaumburg, Illinois
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in Illinois: - Rush University Medical Center — Chicago, Illinois
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University — Chicago, Illinois
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Illinois: - Local Institution - 0278 — Chicago, Illinois
- Local Institution - 0280 — Chicago, Illinois
- Decatur Memorial Hospital — Decatur, Illinois
- Local Institution - 0324 — O'Fallon, Illinois
Phase 2 Recruiting Academic/Other
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in Illinois: - The University of Chicago Medical Center — Chicago, Illinois
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Illinois: - University of Chicago — Chicago, Illinois
- Loyola University — Maywood, Illinois
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Illinois: - University of Illinois Cancer Center — Chicago, Illinois
- The University of Chicago — Chicago, Illinois
Phase 2 Recruiting Industry
The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…
Sponsor: ALX Oncology Inc.
NCT ID: NCT07007559
Sites in Illinois: - City of Hope Chicago — Zion, Illinois
Phase 2 Recruiting Academic/Other
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The nam…
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04468061
Sites in Illinois: - University of Chicago Medical Center — Chicago, Illinois
Phase 2 Recruiting Academic/Other
The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to lea…
Sponsor: Ana C Garrido-Castro, MD
NCT ID: NCT06533826
Sites in Illinois: - University of Chicago Medical Center — Chicago, Illinois
Phase 2 Recruiting Network
The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will prove to be beneficial for women with ea…
Sponsor: Proton Collaborative Group
NCT ID: NCT01766297
Sites in Illinois: - Northwestern Medicine Chicago Proton Center — Warrenville, Illinois
Phase 2 Recruiting Academic/Other
The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research…
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04434040
Sites in Illinois: - University of Chicago Medical Center — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center at Silver Cross Hospital — New Lenox, Illinois
- University of Chicago Medical Center for Advanced Care Orland Park — Orland Park, Illinois
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Illinois: - Ingalls Family Care Center — Calumet City, Illinois
- UChicago Medicine - River East — Chicago, Illinois
- The University Of Chicago — Chicago, Illinois
- University of Chicago Medical Center — Chicago, Illinois
- UChicago Medicine at Ingalls - Flossmoor — Flossmoor, Illinois
Phase 1 Recruiting Industry
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Sponsor: SystImmune Inc.
NCT ID: NCT06293898
Sites in Illinois: - University of Illinois Cancer Center — Chicago, Illinois
- University of Chicago Medicine — Chicago, Illinois
- City of Hope - Chicago — Zion, Illinois
Phase 1 Recruiting Industry
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how …
Sponsor: Eli Lilly and Company
NCT ID: NCT07046923
Sites in Illinois: - The University of Chicago Medical Center (UCMC) — Chicago, Illinois
Phase 1 Recruiting Industry
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with a…
Sponsor: Cogent Biosciences, Inc.
NCT ID: NCT07361562
Sites in Illinois: - Northwestern University — Chicago, Illinois
Phase 1 Recruiting Industry
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT05107674
Sites in Illinois: - University of Chicago — Chicago, Illinois
NA Recruiting Network
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using marke…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03723928
Sites in Illinois: - Saint Anthony's Health — Alton, Illinois
- Rush - Copley Medical Center — Aurora, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Loyola Center for Health at Burr Ridge — Burr Ridge, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Illinois: - OSF Saint Anthony's Health Center — Alton, Illinois
- Rush-Copley Medical Center — Aurora, Illinois
- Advocate Outpatient Center - Aurora — Aurora, Illinois
- Advocate Good Shepherd Hospital — Barrington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Illinois: - Rush-Copley Cancer Care Center — Aurora, Illinois
- Rush-Copley Healthcare Center — Yorkville, Illinois